Bionano Genomics (BNGO) director receives stock option grant for 9,149 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Bionano Genomics director David L. Barker received a new stock option grant as part of his compensation. The award covers 9,149 shares of common stock at an exercise price of $1.19 per share, with no cash paid at grant.

The option vests in equal monthly installments over the 12 months following the grant date and will in any case be fully vested by the date of the company's next annual stockholder meeting, as long as Barker maintains continuous service. The award will also vest in full upon a qualifying Change of Control under the company's 2018 equity incentive plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BARKER DAVID L

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,149	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 9,149 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 9,149 shares Exercise price: $1.19 per share Total options after grant: 9,149 options +2 more

5 metrics

Option grant size 9,149 shares Stock option award to director David L. Barker

Exercise price $1.19 per share Strike price of Barker’s stock option

Total options after grant 9,149 options Holdings following this reported transaction

Option expiration date May 13, 2036 Final expiration of the granted option

Vesting schedule 12 equal monthly installments Vesting over 12 months after grant date

Key Terms

Stock Option, Continuous Service, Change of Control, equity incentive plan

4 terms

Stock Option financial

"Stock Option (Right to Buy)"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Continuous Service financial

"subject to the option holder's Continuous Service through each such vesting date"

Change of Control financial

"will vest in full upon a Change of Control as defined in the plan"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

equity incentive plan financial

"as defined in the Company's 2018 equity incentive plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Form 4 Insider Transactions: What Each Field Means →

05/14/2026 - 06:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BARKER DAVID L

(Last)

(First)

(Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.19	05/14/2026		A		9,149		⁽¹⁾	05/13/2036	Common Stock	9,149	$0	9,149	D

Explanation of Responses:

1. The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan).

	/s/ Jonathan V. Dixon, Attorney-in-Fact	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Bionano Genomics (BNGO) report for David L. Barker?

Bionano Genomics reported that director David L. Barker received a stock option grant for 9,149 shares. The option is a compensation award, not an open-market purchase, and gives him the right to buy common stock at a fixed exercise price.

How many shares are covered by David L. Barker’s new Bionano Genomics (BNGO) option?

The new stock option granted to David L. Barker covers 9,149 shares of Bionano Genomics common stock. These shares are tied to an option award that vests over time, rather than an immediate stock purchase in the open market.

What is the exercise price of David L. Barker’s Bionano Genomics (BNGO) stock option?

The exercise price for David L. Barker’s stock option is $1.19 per share. This means he can choose to buy up to 9,149 Bionano Genomics shares at $1.19 in the future, subject to vesting and other plan conditions.

How does the Bionano Genomics (BNGO) option granted to David L. Barker vest?

The option vests in equal monthly installments over 12 months after the grant date. It will be fully vested by the company’s next annual stockholder meeting if he maintains continuous service, and it fully vests earlier upon a qualifying Change of Control event.

When does David L. Barker’s Bionano Genomics (BNGO) option expire?

David L. Barker’s stock option expires on May 13, 2036. Until that expiration date, and subject to vesting and plan rules, he has the right to buy the underlying Bionano Genomics common shares at the fixed $1.19 exercise price.

Is David L. Barker’s Bionano Genomics (BNGO) Form 4 transaction a buy or a compensation grant?

The Form 4 shows a compensation-related stock option grant, coded as an acquisition (A) rather than an open-market buy. Barker received rights to purchase shares at $1.19, reflecting equity compensation rather than a discretionary stock purchase.